Canada Markets closed

Ultimovacs ASA (ULTI.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
138.20-10.40 (-7.00%)
At close: 4:26PM CEST
Full screen
Previous Close148.60
Bid138.20 x N/A
Ask146.60 x N/A
Day's Range135.40 - 152.80
52 Week Range46.00 - 170.20
Avg. Volume111,774
Market Cap4.423B
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-3.96
Earnings DateNov. 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

    UV1 as add-on therapy to checkpoint inhibitors awarded Fast Track designationProvides for potentially expedited review of UV1Ultimovacs to host webcast at 13.00 CET Thursday, 21 October 2021 OSLO, Norway, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage leader in immune stimulatory vaccines for cancer, announced its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the trea

  • GlobeNewswire

    Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

    80% overall survival rate at 24 months follow-upOSLO, Norway, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced continuing positive topline results in its ongoing U.S.-based Phase I clinical trial evaluating the Company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. The trial had previously

  • GlobeNewswire

    Ultimovacs ASA: Share capital increase related to exercise of options

    Oslo, 12 October 2021, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 5,850 through the issuance of 58,500 new shares, each with a par value of NOK 0.10. The resolution is based on an authorisation to increase the share capital granted by the Company's general meeting on 15 April 2021. The new shares are issued to employees of the Company in connection with the Company's employee incentive program. 45,000 of the new shares are